Open Access Open Access  Restricted Access Subscription Access

An Indispensable Parameters of Hb A1c Test Include Usage, Necessity and Requirements

Muralinath E., Guruprasad M., Madhavi Latha C., Sheethal U., Vyshnavi J., Varsha V., Prathysha M.V.S., Karthik Jayanyj Y.

Abstract


AA haemoglobin A1C (HbA1C) test is a blood test that demonstrates your average level of blood glucose, also termed as blood sugar, over the past two to three months. Glucose is a type of sugar in your blood that comes from the foods you consume. Your cells use glucose for energy. A hormone known as insulin helps glucose get into your cells. If you have diabetes your body doesn't prepare sufficient insulin, or your cells don't use it well. As a result, glucose can't get into your cells, so your blood glucose levels enhance. Glucose in your blood binds with haemoglobin, a protein in your red blood cells. As your blood glucose levels enhance, more of your haemoglobin will be coated along with glucose. An A1C test measures the percentage of your red blood cells that have glucose-coated haemoglobin.


Full Text:

PDF

References


Gilstrap, L. G., Chernew, M. E., Nguyen, C. A., Alam, S., Bai, B., McWilliams, J. M., Landon, B. E., & Landrum, M. B. (2019). Association between clinical practice group adherence to quality measures and adverse outcomes among adult patients with diabetes. JAMA Network Open, 2(8), e199139. https://doi.org/10.1001/jamanetworkopen.2019.9139

Sherwani, S. I., Khan, H. A., Ekhzaimy, A., Masood, A., & Sakharkar, M. K. (2016). Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomarker Insights, 11, 95–104. https://doi.org/10.4137/BMI.S38440

Diabetes Control and Complications Trial Research Group, Nathan, D. M., Genuth, S., Lachin, J., Cleary, P., Crofford, O., Davis, M., Rand, L., & Siebert, C. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine, 329(14), 977–986. https://doi.org/10.1056/NEJM199309303291401

Nathan, D. M., & DCCT/EDIC Research Group. (2014). The Diabetes Control and Complications Trial/epidemiology of diabetes interventions and complications study at 30 years: Overview. Diabetes Care, 37(1), 9–16. https://doi.org/10.2337/dc13-2112

Nathan, D. M. (2021). Realising the long-term promise of insulin therapy: The DCCT/EDIC study. Diabetologia, 64(5), 1049–1058. https://doi.org/10.1007/s00125-021-05438-0

Lachin, J. M., Orchard, T. J., & Nathan, D. M., DCCT/EDIC Research Group. (2014). Update on cardiovascular outcomes at 30 years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Diabetes Care, 37(1), 39–43. https://doi.org/10.2337/dc13-2130

ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Leon, J., Lyons, S. K., Perry, M. L., Prahalad, P., Pratley, R. E., Seley, J. J., Stanton, R. C., … Gabbay, R. A. (2023). Glycemic targets: Standards of care in diabetes—2023. Diabetes Care, 46(Suppl. 1), S97–S110. https://doi.org/10.2337/dc23-S007

American Diabetes Association. (2019). Glycemic targets: Standards of medical care in diabetes—2019. Diabetes Care, 42(Suppl. 1), S61–S70. https://doi.org/10.2337/dc19-S006

Qaseem, A., Wilt, T. J., Kansagara, D., Horwitch, C., Barry, M. J., & Forciea, M. A., Clinical Guidelines Committee of the American College of Physicians. Fitterman, N., Balzer, K., Boyd, C., Humphrey, L. L., Iorio, A., Lin, J., Maroto, M., McLean, R., Mustafa, R., Tufte, J. (2018). Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: A guidance statement update from the American College of Physicians. Annals of Internal Medicine, 168(8), 569–576. https://doi.org/10.7326/M17-3433

Jeppsson, J. O., Kobold, U., Barr, J., Finke, A., Hoelzel, W., Hoshino, T., Miedema, K., Mosca, A., Mauri, P., Paroni, R., Thienpont, L., Umemoto, M., & Weykamp, C., International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). (2002). Approved IFCC reference method for the measurement of HbA1c in human blood. Clinical Chemistry and Laboratory Medicine, 40(1), 78–89. https://doi.org/10.1515/CCLM.2002.013

Weykamp, C., John, W. G., & Mosca, A. (2009). A review of the challenge in measuring hemoglobin A1c. Journal of Diabetes Science and Technology, 3(3), 439–445. https://doi.org/10.1177/193229680900300319

Chen, Z., Shao, L., Jiang, M., Ba, X., Ma, B., & Zhou, T. (2022). Interpretation of HbA1c lies at the intersection of analytical methodology, clinical biochemistry and hematology (Review). Experimental and Therapeutic Medicine, 24(6), 707. https://doi.org/10.3892/etm.2022.11609

Hoelzel, W., Weykamp, C., Jeppsson, J. O., Miedema, K., Barr, J. R., Goodall, I., Hoshino, T., John, W. G., Kobold, U., Little, R., Mosca, A., Mauri, P., Paroni, R., Susanto, F., Takei, I., Thienpont, L., Umemoto, M., & Wiedmeyer, H. M., IFCC Working Group on HbA1c Standardization. (2004). IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: A method-comparison study. Clinical Chemistry, 50(1), 166–174. https://doi.org/10.1373/clinchem.2003.024006

Dhatt, G. S., Agarwal, M. M., & Bishawi, B. (2005). HbA1c: A comparison of NGSP with IFCC transformed values. Clinica Chimica Acta, 358(1–2), 81–86. https://doi.org/10.1016/j.cccn.2005.03.002


Refbacks

  • There are currently no refbacks.